U.S. Stock Market Midday Update: Palatin Tech surges 13.5%, trading volume spikes, market volatility draws attention

U.S. Stock Market Midday Update Palatin Tech, up 13.50%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry AbbVie down 0.77%. Based on recent key news: On December 11, HSBC upgraded AbbVie to Buy and raised the target price to $265, expecting a 19% upside in the stock price. This move reflects market confidence in AbbVie's long-term growth potential, driving stock price volatility. On December 10, Biogen's rating was downgraded to Underweight by HSBC, leading to a decline in its stock price, while AbbVie’s rating was upgraded, indicating a relatively optimistic market attitude towards AbbVie. On December 11, analysts pointed out that a strong economy and potential Federal Reserve rate cuts could provide tailwinds for dividend stocks next year, with AbbVie listed as one of the investment candidates worth considering. Market volatility has intensified, and dividend strategies are under focus. Gilead Sciences down 2.88%. Based on recent key news: On December 12, Gilead Sciences and Arcus Biosciences announced the termination of a late-stage cancer drug combination trial, which failed to show a survival advantage. This news led to a decline in Gilead's stock price. On December 12, Gilead Sciences' board chairman O'Day Daniel Patrick submitted a stock change document, showing a reduction in his shareholding. This move may raise market attention towards the company's internal dynamics. On December 11, Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences with a target price of $150. Despite the maintained rating, market doubts about the company's future performance persist. The biotechnology sector is facing risks of trial failures recently. Forte Pharma up 1.03%. Based on recent key news: On December 11, Forte Pharma's stock price rose 1.03%, with a trading volume reaching $464 million, showing strong market interest in the stock. On December 8, Scotiabank maintained a Buy rating on Forte Pharma with a target price of $495, and analysts' optimistic expectations for the stock may have driven the price increase. No other significant news recently. The pharmaceutical industry has performed strongly lately, with noticeable capital inflows. Stocks with High Market Capitalization in the Industry Amgen down 0.14%, with increased trading volume. Based on recent key news: On December 12, Amgen announced that its new drug Uplizna for treating myasthenia gravis received FDA approval. This news boosted the stock price, as the market holds an optimistic view on the long-term control effects of the new drug. Source: MT Newswires On December 11, Wells Fargo analysts raised Amgen's target price to $325, maintaining a "Hold" rating. This move reflects market confidence in Amgen's future performance. Source: Gelonghui On December 13, Morgan Stanley lowered Amgen's target price to $304, reflecting market concerns about its short-term performance. Source: MT Newswires The biopharmaceutical industry faces regulatory risks, with significant capital inflows